Physician profile
John R Godke
NPI 1447274741
$1,952.39
in general payments reported to CMS, 2019-2025
27 companies · $848 in 2025
The $848 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.24 · 2020: $291 · 2021: $214 · 2022: $70.18 · 2023: $195 · 2024: $311 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,354.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $261.63 | 2025 | Rapiblyk |
| Merck Sharp & Dohme LLC | $231.50 | 2020-2025 | Winrevair |
| Astrazeneca Pharmaceuticals LP | $200.17 | 2022-2025 | Fasenra, Tezspire, Airsupra |
| Insmed, INC. | $159.96 | 2021-2025 | Arikayce, Brinsupri |
| Abbvie INC. | $104.14 | 2021-2025 | |
| Baxter Healthcare | $97.02 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Allergan, INC. | $91.75 | 2019-2020 | |
| United Therapeutics Corporation | $90.53 | 2023-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $85.67 | 2022-2024 | Uptravi |
| Genzyme Corporation | $80.17 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.05 | 2021-2024 | |
| Verona Pharma, INC. | $67.83 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.60 | 2020-2024 | Ofev |
| La Jolla Pharmaceutical Company | $42.90 | 2024-2025 | Giapreza |
| Advanced Respiratory, INC | $42.67 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $34.75 | 2023-2024 | Nucala |
| Regeneron Healthcare Solutions, INC. | $32.59 | 2023 | Dupixent |
| Lungpacer Medical USA INC | $31.07 | 2025 | Aeropace Neurostimulation Console |
| Viatris Specialty LLC | $28.54 | 2025 | Yupelri |
| Grifols USA, LLC | $28.42 | 2025 | Prolastin-C Liquid |
| Scpharmaceuticals INC. | $25.43 | 2024 | |
| Astellas Pharma US INC | $19.30 | 2021 | |
| Mylan Specialty L.P. | $18.44 | 2023 | Yupelri |
| Philips North America LLC | $15.74 | 2024 | (Ak6) Vest Therapy |
| Vapotherm INC | $15.20 | 2020 | |
| Inspire Medical Systems, INC. | $13.94 | 2025 | Inspire |
| Gilead Sciences, INC. | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Godke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.